Format

Send to

Choose Destination
J Pharmacol Exp Ther. 2013 Nov;347(2):325-38. doi: 10.1124/jpet.113.205799. Epub 2013 Aug 21.

Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Author information

1
Institute for Neurodegenerative Diseases (D.L., K.G., Z.L., S.R., J.R.G., M.G., M.L.E., S.J.D., B.M.S., S.B.P.), Department of Neurology (K.G., Z.L., S.R., J.R.G., B.M.S., S.B.P.), Department of Pathology (A.O., S.J.D.), Department of Pharmaceutical Chemistry (E.D., C.B., A.R.R., M.P.J.), Department of Bioengineering and Therapeutic Sciences (B.M.S.), and Small Molecule Discovery Center (C.B., A.R.R.), University of California, San Francisco, California.

Abstract

The only small-molecule compound demonstrated to substantially extend survival in prion-infected mice is a biaryl hydrazone termed "Compd B" (4-pyridinecarboxaldehyde,2-[4-(5-oxazolyl)phenyl]hydrazone). However, the hydrazone moiety of Compd B results in toxic metabolites, making it a poor candidate for further drug development. We developed a pharmacophore model based on diverse antiprion compounds identified by high-throughput screening; based on this model, we generated biaryl amide analogs of Compd B. Medicinal chemistry optimization led to multiple compounds with increased potency, increased brain concentrations, and greater metabolic stability, indicating that they could be promising candidates for antiprion therapy. Replacing the pyridyl ring of Compd B with a phenyl group containing an electron-donating substituent increased potency, while adding an aryl group to the oxazole moiety increased metabolic stability. To test the efficacy of Compd B, we applied bioluminescence imaging (BLI), which was previously shown to detect prion disease onset in live mice earlier than clinical signs. In our studies, Compd B showed good efficacy in two lines of transgenic mice infected with the mouse-adapted Rocky Mountain Laboratory (RML) strain of prions, but not in transgenic mice infected with human prions. The BLI system successfully predicted the efficacies in all cases long before extension in survival could be observed. Our studies suggest that this BLI system has good potential to be applied in future antiprion drug efficacy studies.

PMID:
23965382
PMCID:
PMC3807058
DOI:
10.1124/jpet.113.205799
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center